The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative Review
DOI: https://doi.org/10.2147/JPR.S371337
IF: 2.8319
2022-10-25
Journal of Pain Research
Abstract:Ann Colosia, 1 Annete Njue, 2 Zahid Bajwa, 3 Erika Dragon, 4 Rebecca L Robinson, 5 Kristin M Sheffield, 5 Sheena Thakkar, 6 Steven H Richiemer 7 1 Department of Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; 2 Department of Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, UK; 3 Medical Affairs, Eli Lilly and Company, Indianapolis, IN, USA; 4 Medical Affairs, Pfizer, Ltd, Budapest, Hungary; 5 Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; 6 Patient Health & Impact, Pfizer Inc, New York, NY, USA; 7 Division of Pain Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA Correspondence: Rebecca L Robinson, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA, Tel +1 3174331323, Fax +1 3172777444, Email Bone pain is one of the most common forms of pain reported by cancer patients with metastatic disease. We conducted a review of oncology literature to further understand the epidemiology of and treatment approaches for metastatic cancer–induced bone pain and the effect of treatment of painful bone metastases on the patient's quality of life. Two-thirds of patients with advanced, metastatic, or terminal cancer worldwide experience pain. Cancer pain due to bone metastases is the most common form of pain in patients with advanced disease and has been shown to significantly reduce patients' quality of life. Treatment options for cancer pain due to bone metastases include nonsteroidal anti-inflammatory drugs, palliative radiation, bisphosphonates, denosumab, and opioids. Therapies including palliative radiation and opioids have strong evidence supporting their efficacy treating cancer pain due to bone metastases; other therapies, like bisphosphonates and denosumab, do not. There is sufficient evidence that patients who experience pain relief after radiation therapy have improved quality of life; however, a substantial proportion are nonresponders. For those still requiring pain management, even with available analgesics, many patients are undertreated for cancer pain due to bone metastases, indicating an unmet need. The studies in this review were not designed to determine why cancer pain due to bone metastases was undertreated. Studies specifically addressing cancer pain due to bone metastases, rather than general cancer pain, are limited. Additional research is needed to determine patient preferences and physician attitudes regarding choice of analgesic for moderate to severe cancer pain due to bone metastases. Keywords: cancer, pain, bone, metastasis, quality of life, cancer patients Bone metastases are a significant contributor to the cancer-induced pain felt by over half of patients with metastatic cancer. 1,2 In fact, bone pain is often the initial symptom of bone metastasis. 3,4 The pain may come and go at first, becoming constant and gradually intensifying with time. 5 Patients often experience worsening background pain in the months leading up to a diagnosis of bone metastasis. 6 After a bone metastasis diagnosis, the proportion of patients experiencing pain may continue to rise at a slower rate than before diagnosis, likely as a result of more intensive patient management, including the introduction or intensification of pain medications. 6 Severe spontaneous (ie breakthrough) pain occurs frequently, with acute and unpredictable occurrence and severity. 5 Higher pain levels correlate with greater functional impairment. 7 Metastatic cancer–induced bone pain (mCIBP) is caused by inflammation and bone remodeling (nociceptive pain) or by damage to or dysfunction of the nervous system (neuropathic pain) due to tumor invasion. 8,9 Increasingly, research indicates that cancer-induced bone pain is often a combination of neuropathic and nociceptive pain, rather than distinct neurochemical events. 10 Pain from persistent nerve activation or damage from bone metastases may result in peripheral or central sensitization. 9 Cancer pain due to bone metastases may be background (tonic) pain, spontaneous at rest, related to movement (incident pain), or breakthrough pain, defined as a transitory flare of pain superimposed on an otherwise stable pattern under opioid therapy. 7,11 These types of pain may be present alone or in combination. Incident pain can be managed by increasing the opioid dose above that which is effective for controlling pain at rest. 11 Breakthrough pain is often unpredictable, sudden in onset (< 5 minutes from start of pain escalation until maximum pain), of short durati -Abstract Truncated-
clinical neurology